Analysts Recommended this Stock: Intellia Therapeutics Inc. (NTLA)

James Marshall
November 4, 2017

Current levels places Intellia Therapeutics Inc. During last 3 month period, 2.81% of total institutional ownership has changed in the company shares. On August 29 the stock rating was downgraded from "Buy" to "Neutral" in an announcement from Chardan Capital. Analysts expect next quarter's EPS to be $-0.46 with next year's EPS projected to be $-2.06. Intellia Thera... had 17 analyst reports since May 31, 2016 according to SRatingsIntel.

Intellia Therapeutics, Inc is a genome editing company. Janney Capital initiated the stock with "Buy" rating in Thursday, September 29 report. (NASDAQ:NTLA) stock. Many analysts use price trends and patterns to predict future performance, and we can glean some important insights about NTLA by examining the chart. According to today's trading volume Intellia Therapeutics ABOVE its 20-Day Avg. volume with the stock showing ABOVE Abnormal volume in the past 150 days. Wedbush reiterated an "ourperform" rating and issued a $25.00 price objective (down from $29.00) on shares of Intellia Therapeutics in a report on Wednesday, September 27th. Zacks Investment Research raised Intellia Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, August 30th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. If you are reading this news story on another publication, it was illegally stolen and republished in violation of worldwide copyright & trademark legislation. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and worldwide copyright and trademark law. Intellia Therapeutics Inc. (NTLA) average trading volume of 745,880 during the past month is 146.28% above its average volume over the past year, indicating that investors have been more active than usual in the stock in recent times. Over the last week of the month, it was -20.30%, 30.43% over the last quarter, and 53.96% for the past six months.

The market capitalization (Stock Price Multiply by Total Number of Outstanding Shares) for the company is reported at $724.50M. The firm had revenue of $7.30 million during the quarter, compared to analysts' expectations of $5.83 million. During the same period in the prior year, the company posted ($0.22) earnings per share. The company's quarterly revenue was up 49.0% compared to the same quarter a year ago. The 50 day moving average was up by +2.51% and the 200 day average went up $0.78 or +2.94%. Vanguard Group Inc. now owns 997,288 shares of the company's stock worth $15,957,000 after purchasing an additional 92,580 shares during the last quarter. Meeder Asset Management Inc cut its position by selling 149 shares a decrease of 46.9% in the quarter. Bank of Montreal Can increased its position in Intellia Therapeutics by 1,031.7% in the second quarter. Temasek Holdings Private Ltd bought a new position in shares of Intellia Therapeutics during the second quarter valued at about $16,878,000. Finally, State Street Corp boosted its position in Intellia Therapeutics by 52.0% in the second quarter. Institutional owners hold 48.40% stake in the company, while insiders ownership held at 3.60%. The Return on Equity ratio of Intellia Therapeutics Inc. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular fix process to knockout, fix or insert a gene.

Other reports by Click Lancashire

Discuss This Article